Phytotherapy, an ancient practice based on the use of plant-based products, has recently seen a strong resurgence, driven by a growing preference for “natural” products. In the context of community pharmacy, it is presented as an alternative or complement to conventional treatments, especially for mild or chronic conditions, or as an adjuvant for serious illnesses. However, its use is not without risks, due to the variability in the composition of marketed products, the pharmacological action of their active ingredients, and the lack of uniform regulatory framework. There are different legal categories for these products, depending on their composition, indication, and scientific backing. Some, such as dietary supplements and medical devices, are available without medical supervision despite containing active ingredients used in prescription medications.
The growing use of phytotherapy and the increasing heterogeneity of available formulations require community pharmacists to critically assess marketed products based on criteria of quality, safety, and efficacy. To design an operational protocol to support community pharmacists in the evaluation and decision-making process regarding plant-based products. A consensus process was conducted by the SEFAC Fitoterapia Commission, involving the development and integration of structured checklists and the selection of open-access data sources. A decision tree was defined, starting from the legal classification, and an analytical framework for product evaluation was established. Finally, a rapid reporting template was designed for use in community pharmacy practice. The resulting protocol provides a structured approach to the evaluation of phytotherapeutic products, organized into five sections and a rapid report. It is based on a sequential assessment of legal classification, scientific evidence, quality, safety, and patient information. Its implementation is supported by official, reliable, and openly accessible databases available to community pharmacists. The proposed protocol facilitates consistent and traceable pharmaceutical decision-making by integrating regulatory and scientific information into a practical and applicable tool for community pharmacy.
Justification There is a lack of studies on the physical wear and mental exhaustion experienced by community pharmacists (CPs) in the workplace, so we consider it necessary to assess its relevance. Objective To analyze the prevalence and significance of occupational burnout syndrome in community pharmacies in Galicia, its risk factors, and its association with work-related and demographic variables. Methods Design: Cross-sectional observational study conducted from September to December 2025. Approved by the Galicia Research Ethics Committee (CEIC Galicia). Subjects: Pharmacists practicing in community pharmacies. Sample size: For a precision of 10.0% in estimating a proportion, assuming a prevalence of 50.0% and a total population size of 3,984, it will be necessary to include 94 participants in the study. Variables: Proportion of CPs affected by burnout syndrome and mean level of affectation according to the total score of the Maslach Burnout Inventory (MBI-HSS). Scores for the sections on considerations and expectations regarding professional practice: frequency (%). Procedure: An online questionnaire was created using Microsoft Forms®. The sample was stratified by province and place of practice according to the classification established by the Xunta de Galicia into three population zone types: densely populated, intermediate, and sparsely populated. Pharmacies will be contacted by phone to offer one pharmacist the opportunity to participate in the study. If they agree, a link to the form and instructions will be sent to their email. Applicability The aim is to establish a starting point to raise awareness and facilitate the approach to burnout syndrome among CPs. This will make it possible to develop prevention and coping strategies.